Work

TIGER-3: A phase 3, open-label, randomized study of rociletinib vs cytotoxic chemotherapy in patients (pts) with mutant EGFR non-small cell lung cancer (NSCLC) progressing on prior EGFR TKI therapy and doublet chemotherapy.

Year: 2015

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2015.33.15_suppl.tps8109

Authors: James Chih-Hsin Yang, Sanjay Popat, Panos Georgiou, Emiko Miyamoto, Jeffrey D. Isaacson, Heather A. Wakelee

Institutions: National Taiwan University, National Taiwan University Hospital, Royal Marsden Hospital, Clovis Oncology (United Kingdom), Clovis Oncology (United States), Stanford Medicine, Stanford Cancer Institute, Stanford University

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2581817452

Cites:

Cited by: 2

Related to: 10